Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA5A | P35218 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.32 |
| ▸ | FCGR3B | O75015 | 1/20 | 0.31 |
| ▸ | FCGR1A | P12314 | 1/20 | 0.31 |
| ▸ | FCGR2A | P12318 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15019811 | 0.88 | DNM1 (0.40) | DNM1CA1CA2CA12CA5A | |
| SCHEMBL15039541 | 0.88 | DNM1 (0.40) | DNM1CA1CA2CA12CA5A | |
| SCHEMBL15020067 | 0.81 | DNM1 (0.42) | DNM1PTGS1PTGS2 | |
| SCHEMBL15039580 | 0.81 | DNM1 (0.42) | DNM1PTGS1PTGS2 | |
| SCHEMBL15020065 | 0.81 | DNM1 (0.42) | DNM1PTGS1PTGS2 | |
| SCHEMBL15039543 | 0.78 | DNM1 (0.40) | DNM1PTGS1PTGS2 | |
| SCHEMBL11311903 | 0.78 | PTGS1 (0.34) | PTGS1PTGS2CA1CA2 | |
| SCHEMBL15039793 | 0.77 | DNM1 (0.40) | DNM1PTGS1PTGS2 | |
| SCHEMBL15039790 | 0.77 | DNM1 (0.49) | DNM1PTGS1PTGS2 | |
| SCHEMBL15022915 | 0.77 | DNM1 (0.50) | DNM1CA1CA2CA12CA5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9554977-B2 | Triaromatic azomethine direct dyes, dye composition comprising at least one such dye, method of implementation and use | L'OREAL (FR) | 2017-01-31 | — | — | US | disclosed |
| US-9554977-B2 | Triaromatic azomethine direct dyes, dye composition comprising at least one such dye, method of implementation and use | L'OREAL (FR) | 2017-01-31 | — | — | US | disclosed |
| US-20150320660-A1 | TRIAROMATIC AZOMETHINE DIRECT DYES, DYE COMPOSITION COMPRISING AT LEAST ONE SUCH DYE, METHOD OF IMPLEMENTATION AND USE | L'OREAL (FR) | 2015-11-12 | — | — | US | disclosed |
| WO-2013087768-A1 | TRIAROMATIC AZOMETHINE DIRECT DYES, DYE COMPOSITION COMPRISING AT LEAST ONE SUCH DYE, METHOD OF IMPLEMENTATION AND USE | L'OREAL (FR) | 2013-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150320660-A1 | TRIAROMATIC AZOMETHINE DIRECT DYES, DYE COMPOSITION COMPRISING AT LEAST ONE SUCH DYE, METHOD OF IMPLEMENTATION AND USE | KRT18, MKI67, CDC73 | DNM1 2808/4885PTGS1 2413/4885PTGS2 3236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.